Form D · Biotechnology
ECLIPSE BIOINNOVATIONS, INC.
San Diego, CA · CIK 0001881936
Offering snapshot reported Nov 20, 2025 · SEC filing
- Reported sold
- $4.91M Offering amount: $7.24M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 5, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 20, 2025 | Initial | $4,905,886 | No comparison | 7 | SEC filing |
| Sep 10, 2021 | Initial | $11,950,024 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-564566
Total Amount Sold includes $4,235,076.39 of cancellation of convertible securities and $670,809.39 of new cash.
Source: Form D, filed Nov 20, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Chu | Director, Executive |
| Hallie Kuhn | Director |
| Eric L Van Nostrand | Director |
| Daniel Vasella | Director |
| Edmond Wong | Director |
| Eugene Yeo | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5770 Oberlin Dr.
San Diego, CA, 92121
San Diego, CA, 92121